Weekly Recap: Q2 2026 report & webcast and ISL/LEN Week 48 suppression
Gilead Sciences, Inc. (NASDAQ:GILD) will report Q2 2026 results Aug. 4 with a 4:30 PM ET webcast as data show its ISL/LEN weekly and PURPOSE twice‑yearly lenacapavir regimens sustain viral suppression and adherence, while EMA backs Trodelvy+Keytruda for PD‑L1+ TNBC, EU decision due 2026.Previous We…